As the first biologic approved for atopic dermatitis, dupilumab revolutionized treatment protocols. It specifically inhibits IL-4 and IL-13 signaling pathways, key drivers of inflammation. Patients report significant symptom reduction, less frequent flare-ups, and improvements in sleep quality. Long-term studies continue to reinforce dupilumab's safety and efficacy, with ongoing research exploring its potential in other atopic conditions such as asthma and nasal polyposis. Clinicians now have a powerful tool for severe cases, especially those unresponsive to conventional therapies.

Other promising biologics like tralokinumab and lebrikizumab have recently gained FDA approval or are under review. These agents target distinct interleukin pathways, expanding options for personalized treatment. Their differential mechanisms allow clinicians to select therapies based on disease severity, patient preferences, and response patterns. Real-world evidence indicates these drugs are well tolerated and highly effective in reducing atopic dermatitis severity, emphasizing the importance of continued innovation.

JAK inhibitors such as abrocitinib and upadacitinib represent a new class of oral medications. They interfere with intracellular signaling pathways involved in inflammatory cytokine production. Clinical trials demonstrate rapid symptomatic relief and sustained skin clearance. These medicines introduce flexibility in treatment, especially for patients seeking alternatives to injectable biologics. While effective, JAK inhibitors pose safety considerations like thromboembolism and infections, necessitating vigilant patient monitoring and risk assessment.